Martin Giedlin, Ph.D.

Vice President, Technical Operations

Dr. Giedlin brings more than 20 years of experience supporting immunotherapy options for cancer and infectious disease through the development of recombinant proteins, monoclonal antibodies, gene therapy and vaccines. He most recently served as executive director, process sciences, in Novartis Pharmaceuticals’ Cell and Gene Therapy group that focused on gene-editing of autologous T cells. He also served as vice president, development, at Sangamo Inc., which used zinc-fingered proteins for both cellular and vector-mediated gene-editing to generate therapies for the treatment of genetic and infectious disease. Prior to that he served as senior director, in vivo biology, at Cerus Corporation and Onyx Pharmaceuticals Inc. Dr. Giedlin received his Ph.D. in microbiology from the Medical College of Virginia (Virginia Commonwealth University) and his B.S. in biology and chemistry from the University of Notre Dame in Indiana.